SALARIUS PHARMACEUTICALS INC (SLRX)
US79400X3052 - Common Stock
Overall SLRX gets a fundamental rating of 1 out of 10. We evaluated SLRX against 588 industry peers in the Biotechnology industry. SLRX has a bad profitability rating. Also its financial health evaluation is rather negative. SLRX is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
SLRX had negative earnings in the past year.
SLRX had a negative operating cash flow in the past year.
SLRX had negative earnings in each of the past 5 years.
In the past 5 years SLRX always reported negative operating cash flow.
1.2 Ratios
The Return On Assets of SLRX (-190.42%) is worse than 89.21% of its industry peers.
The Return On Equity of SLRX (-237.21%) is worse than 71.58% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -190.42% | ||
| ROE | -237.21% | ||
| ROIC | N/A |
ROA(3y)-145.82%
ROA(5y)-103.7%
ROE(3y)-191.58%
ROE(5y)-135.06%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for SLRX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
The number of shares outstanding for SLRX has been increased compared to 1 year ago.
SLRX has more shares outstanding than it did 5 years ago.
SLRX has a worse debt/assets ratio than last year.
2.2 Solvency
SLRX has an Altman-Z score of -20.75. This is a bad value and indicates that SLRX is not financially healthy and even has some risk of bankruptcy.
SLRX has a worse Altman-Z score (-20.75) than 86.30% of its industry peers.
A Debt/Equity ratio of 0.05 indicates that SLRX is not too dependend on debt financing.
SLRX's Debt to Equity ratio of 0.05 is on the low side compared to the rest of the industry. SLRX is outperformed by 61.30% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -20.75 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
A Current Ratio of 5.02 indicates that SLRX has no problem at all paying its short term obligations.
SLRX has a Current ratio of 5.02. This is comparable to the rest of the industry: SLRX outperforms 54.62% of its industry peers.
A Quick Ratio of 5.02 indicates that SLRX has no problem at all paying its short term obligations.
The Quick ratio of SLRX (5.02) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 5.02 | ||
| Quick Ratio | 5.02 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 69.24% over the past year.
EPS 1Y (TTM)69.24%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q92.1%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Revenue growth Q2QN/A
3.2 Future
Based on estimates for the next years, SLRX will show a small growth in Earnings Per Share. The EPS will grow by 5.22% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-420.39%
EPS Next 2Y-113.61%
EPS Next 3Y5.22%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
SLRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year SLRX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-113.61%
EPS Next 3Y5.22%
5. Dividend
5.1 Amount
No dividends for SLRX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
SALARIUS PHARMACEUTICALS INC
NASDAQ:SLRX (4/26/2024, 7:16:30 PM)
After market: 0.4771 -0.02 (-3.64%)0.4951
0 (-0.78%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap2.13M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -190.42% | ||
| ROE | -237.21% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.05 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 5.02 | ||
| Quick Ratio | 5.02 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)69.24%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y-420.39%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y